Market Overview:
The global toxoid vaccines market is expected to grow at a CAGR of 7.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing incidence of infectious diseases, rising demand for preventive healthcare measures, and growing awareness about immunization and vaccination programs. Based on type, the global toxoid vaccines market is segmented into monovalent tetanus toxoid (TT), diphtheria, tetanus, pertussis (DTaP), diphtheria and tetanus (DT), and others. The DTaP segment is expected to account for the largest share of the global toxoid vaccines market in 2018 owing to its high usage rates across all age groups. Based on application, the global toxoid vaccines market is segmented into hospitals and clinics, government organizations, research institutions/laboratories/academic institutes,,and others including private clinics). In terms of geography,.However,.
Product Definition:
A toxoid vaccine is a vaccine that uses an inactivated toxin or modified toxin to produce immunity. Toxoid vaccines are used to protect against diseases caused by bacteria, such as tetanus and diphtheria. The importance of toxoid vaccines is that they can protect people from serious diseases caused by bacteria.
Monovalent Tetanus Toxoid (TT):
Monovalent tetanus toxoid is a vaccine developed by the World Health Organization (WHO) to prevent against tetanus. It was first approved in 1990 in the European Union and since then it has been used extensively across Europe, Africa, Asia Pacific and Latin America regions.
Diphtheria:
Diphtheria is an infectious disease caused by the diphtheria toxin. The symptoms include sore throat, high fever, and neck stiffness. In severe cases, it may lead to heart problems or even death. Diphtheria vaccine consists of a protein molecule that stimulates the body’s immune system to produce antibodies against the diphtheria toxin and prevent its symptoms from occurring in patients suffering from colds or allergies.
Application Insights:
Based on application, the global toxoid vaccines market has been segmented into hospitals and clinics, government organizations, research institutes and companies. Hospitals and clinics held the largest share in 2017 owing to factors such as increasing number of immunization programs conducted by public health authorities for various diseases.
DTaP is one of the most widely used vaccine brands across the globe due to its high effectiveness against pertussis infection along with being a part of every child¢â‚¬â„¢s schedule. The DTaP vaccination program is active in more than 40 countries around the world with more than 90% coverage rate among infants aged between 12-15 months old. This factor is anticipated to drive demand over next few years.
The hospital based immunization program against diphtheria uses an acellular version (DTP) while those administered through clinics use whole cell version (DT).
Regional Analysis:
North America dominated the global market in 2017. The presence of well-established healthcare infrastructure and high awareness levels coupled with relatively higher spending capabilities of the population are some factors responsible for its large share. Moreover, government initiatives to control infectious diseases by increasing immunization rates is expected to fuel regional growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising incidences of vaccine-preventable diseases coupled with growing investments by governments and private players in this region. For instance, GlaxoSmithKline (GSK) has invested around USD X million for research on new vaccines against Japanese encephalitis virus in India since 2010, which indicates a significant increase in such activities across this region over time. Such investments are further expected to boost revenue generation from Asia Pacific during the forecast period as it approaches’s 2030 Olympics year’s end; however, COVID 19 outbreak may hinder progress significantly between 2018 & 2020).
Growth Factors:
- Increasing incidence of infectious diseases: The increasing incidence of infectious diseases is one of the major growth drivers for the toxoid vaccines market. Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, and parasites. These infections can cause a wide range of symptoms such as fever, diarrhea, vomiting, and skin rashes. The increasing incidence of these infections is driving the demand for toxoid vaccines globally.
- Growing awareness about preventive measures: There is a growing awareness among people about preventive measures against infectious diseases. This has led to an increase in the demand for toxoid vaccines globally. Toxoid vaccines offer protection against various types of bacterial infections and are considered to be more effective than other types of vaccine available in the market today.
Scope Of The Report
Report Attributes
Report Details
Report Title
Toxoid Vaccines Market Research Report
By Type
Monovalent Tetanus Toxoid (TT), Diphtheria, Tetanus, Pertussis (DTaP), Diphtheria and Tetanus (DT),
By Application
Hospitals And Clinics, Government Organizations, Research, Others,
By Companies
GlaxoSmithKline, Merck, Pfizer, Sanofi Pasteur, AstraZeneca, Bharat Biotech, Shenzhen Kangtai Biological Products, Bausch Health, Emergent Biosolutions, Astellas Pharma, Panacea Biotec
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Toxoid Vaccines Market Report Segments:
The global Toxoid Vaccines market is segmented on the basis of:
Types
Monovalent Tetanus Toxoid (TT), Diphtheria, Tetanus, Pertussis (DTaP), Diphtheria and Tetanus (DT),
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals And Clinics, Government Organizations, Research, Others,
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- GlaxoSmithKline
- Merck
- Pfizer
- Sanofi Pasteur
- AstraZeneca
- Bharat Biotech
- Shenzhen Kangtai Biological Products
- Bausch Health
- Emergent Biosolutions
- Astellas Pharma
- Panacea Biotec
Highlights of The Toxoid Vaccines Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monovalent Tetanus Toxoid (TT)
- Diphtheria
- Tetanus
- Pertussis (DTaP)
- Diphtheria and Tetanus (DT)
- By Application:
- Hospitals And Clinics
- Government Organizations
- Research
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Toxoid Vaccines Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Toxoid vaccines are created from toxins that have been isolated and purified. These vaccines help protect people from diseases caused by the toxin.
Some of the key players operating in the toxoid vaccines market are GlaxoSmithKline, Merck, Pfizer, Sanofi Pasteur, AstraZeneca, Bharat Biotech, Shenzhen Kangtai Biological Products, Bausch Health, Emergent Biosolutions, Astellas Pharma, Panacea Biotec.
The toxoid vaccines market is expected to grow at a compound annual growth rate of 7.8%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Toxoid Vaccines Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Toxoid Vaccines Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Toxoid Vaccines Market - Supply Chain
4.5. Global Toxoid Vaccines Market Forecast
4.5.1. Toxoid Vaccines Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Toxoid Vaccines Market Size (000 Units) and Y-o-Y Growth
4.5.3. Toxoid Vaccines Market Absolute $ Opportunity
5. Global Toxoid Vaccines Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Toxoid Vaccines Market Size and Volume Forecast by Type
5.3.1. Monovalent Tetanus Toxoid (TT)
5.3.2. Diphtheria
5.3.3. Tetanus
5.3.4. Pertussis (DTaP)
5.3.5. Diphtheria and Tetanus (DT)
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Toxoid Vaccines Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Toxoid Vaccines Market Size and Volume Forecast by Application
6.3.1. Hospitals And Clinics
6.3.2. Government Organizations
6.3.3. Research
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Toxoid Vaccines Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Toxoid Vaccines Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Toxoid Vaccines Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Toxoid Vaccines Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Toxoid Vaccines Demand Share Forecast, 2019-2026
9. North America Toxoid Vaccines Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Toxoid Vaccines Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Toxoid Vaccines Market Size and Volume Forecast by Application
9.4.1. Hospitals And Clinics
9.4.2. Government Organizations
9.4.3. Research
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Toxoid Vaccines Market Size and Volume Forecast by Type
9.7.1. Monovalent Tetanus Toxoid (TT)
9.7.2. Diphtheria
9.7.3. Tetanus
9.7.4. Pertussis (DTaP)
9.7.5. Diphtheria and Tetanus (DT)
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Toxoid Vaccines Demand Share Forecast, 2019-2026
10. Latin America Toxoid Vaccines Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Toxoid Vaccines Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Toxoid Vaccines Market Size and Volume Forecast by Application
10.4.1. Hospitals And Clinics
10.4.2. Government Organizations
10.4.3. Research
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Toxoid Vaccines Market Size and Volume Forecast by Type
10.7.1. Monovalent Tetanus Toxoid (TT)
10.7.2. Diphtheria
10.7.3. Tetanus
10.7.4. Pertussis (DTaP)
10.7.5. Diphtheria and Tetanus (DT)
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Toxoid Vaccines Demand Share Forecast, 2019-2026
11. Europe Toxoid Vaccines Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Toxoid Vaccines Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Toxoid Vaccines Market Size and Volume Forecast by Application
11.4.1. Hospitals And Clinics
11.4.2. Government Organizations
11.4.3. Research
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Toxoid Vaccines Market Size and Volume Forecast by Type
11.7.1. Monovalent Tetanus Toxoid (TT)
11.7.2. Diphtheria
11.7.3. Tetanus
11.7.4. Pertussis (DTaP)
11.7.5. Diphtheria and Tetanus (DT)
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Toxoid Vaccines Demand Share, 2019-2026
12. Asia Pacific Toxoid Vaccines Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Toxoid Vaccines Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Toxoid Vaccines Market Size and Volume Forecast by Application
12.4.1. Hospitals And Clinics
12.4.2. Government Organizations
12.4.3. Research
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Toxoid Vaccines Market Size and Volume Forecast by Type
12.7.1. Monovalent Tetanus Toxoid (TT)
12.7.2. Diphtheria
12.7.3. Tetanus
12.7.4. Pertussis (DTaP)
12.7.5. Diphtheria and Tetanus (DT)
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Toxoid Vaccines Demand Share, 2019-2026
13. Middle East & Africa Toxoid Vaccines Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Toxoid Vaccines Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Toxoid Vaccines Market Size and Volume Forecast by Application
13.4.1. Hospitals And Clinics
13.4.2. Government Organizations
13.4.3. Research
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Toxoid Vaccines Market Size and Volume Forecast by Type
13.7.1. Monovalent Tetanus Toxoid (TT)
13.7.2. Diphtheria
13.7.3. Tetanus
13.7.4. Pertussis (DTaP)
13.7.5. Diphtheria and Tetanus (DT)
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Toxoid Vaccines Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Toxoid Vaccines Market: Market Share Analysis
14.2. Toxoid Vaccines Distributors and Customers
14.3. Toxoid Vaccines Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. GlaxoSmithKline
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Sanofi Pasteur
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. AstraZeneca
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Bharat Biotech
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Shenzhen Kangtai Biological Products
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Bausch Health
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Emergent Biosolutions
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Astellas Pharma
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. Panacea Biotec
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
